Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster II
Hematology Disease Topics & Pathways:
Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, DLBCL, Biological Processes, Lymphoid Malignancies, Clinically relevant, immune mechanism, microenvironment
Methods: The OX40 mRNA expression between DLBCL tissues and normal tissues, and its associated with survival were analyzed through Oncomine databases, including the Basso lymphoma dataset (n=57), the Compagno lymphoma dataset (n=64) and the Dave lymphoma dataset (n=233). The GEO2R online analysis was utilized to acquire the differentially expressed genes (DEGs) in the OX40 mRNA high and low expression groups, and GO and KEGG functional enrichment analysis on these DEGs using Omicshare tool were further performed. The CD4, CD8, Pax-5, OX40 and Foxp3 multiplexed immunofluorescence staining, and quantitative analyses of OX40+ tumor-infiltrating T-lymphocytes, including CD4+ T-cells, CD8+ T-cells, and Tregs, were performed in DLBCL biopsy samples.
Results: We found that the OX40 mRNA expression was significantly upregulated in DLBCL patients compared to that of normal lymphoid tissues through Oncomine (p<0.001), and high OX40 mRNA expression was significantly correlated with the favorable prognosis (p=0.018). The 45 up-regulated and 4 down-regulated genes were identified as to be significantly associated with OX40 expression (p<0.05). GO analysis results showed that changes in biological processes (BP) of DEGs were significantly enriched in the activation and regulation of T cells and other lymphocytes. Changes in molecular function (MF) were mainly enriched in tumor necrosis factor-activated receptor activity and chemokine receptor binding. Changes in cell component (CC) of DEGs were mainly enriched in the external side of membrane and immunological synapse. KEGG pathway analysis revealed that the DEGs were mainly enriched in the cytokine-cytokine receptor interaction, T cell receptor signaling pathway, chemokine signaling pathway, and NF-κB signaling pathway. The total OX40+ cells expression level in patients was significantly associated with Ann Arbor stage (p=0.039) and IPI score (p=0.047). The expression of OX40, compared with that in stable disease (SD)/progressive disease (PD) patients, was significantly increased in complete response (CR) or partial response (PR) patients (p=0.002; p=0.002, respectively). A higher total expression of OX40 and a greater number of CD8+/OX40+ T-cells were significantly correlated with longer overall survival (OS) (p=0.008; p=0.004, respectively). The expression of CD8+/OX40+ T-cells maintained prognostic value for OS in multivariate analysis (p=0.030; p=0.024, respectively).
Conclusions: Here, for the first time, we describes the expression characteristics of OX40 and tumor microenvironment in DLBCL and demonstrates that the infiltration strength of OX40+ T-cells—particularly the infiltration strength of OX40-expressing CD8+ T-cells on DLBCL—has a significant impact on survival. DLBCL patients may benefit from the OX40 agonist antibodies and may enhancement of the efficacy of existing immune checkpoint inhibition therapies, providing a theoretical foundation for the potential clinical transformational application value of OX40 agonists for DLBCL therapy.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts